Monoclonal antibodyFDA-approvedSecond-line
Panitumumab
How it works
Binds the epidermal growth factor receptor (EGFR) on cancer cells, blocking growth signals and flagging the cells for immune destruction.
Cancer types
Colorectal Cancer— Wild-type KRAS
Efficacy
Studies show that panitumumab can achieve response rates of around 10% in patients with metastatic colorectal cancer and EGFR-expressing tumors.
Side effects
Moderate
Side effects can be significant and may require dose adjustments or supportive medication, but the treatment is usually continued.
Evidence from research
| Study | Cancer type | Stage | Efficacy | |
|---|---|---|---|---|
| Testing Two Cancer Treatments in a Different Order | Colorectal Cancer | phase-2 | — | Source → |
| Pancreatic Cancer Trial Examines Chemotherapy with or without Panitumumab | Pancreatic Cancer | phase-3 | — | Source → |
| Panitumumab-IRDye800 Trial for Pancreatic Cancer Patients Undergoing Surgery | Pancreatic Cancer | phase-1 | — | Source → |
| Early Magnesium Supplementation Helps Manage Hypomagnesemia in Colorectal Cancer Patients | Colorectal Cancer | observational | The incidence of grade 3 or higher hypomagnesemia was significantly lower in the post-protocol group than in the pre-protocol group (3.3% vs. 30.0%). | Source → |
| New Cancer Treatment Shows Promise in Advanced Colorectal Cancer | Colorectal Cancer | phase-3 | The overall response rates were 30.2% for sotorasib 960 mg-panitumumab, 7.5% for sotorasib 240 mg-panitumumab, and 1.9% for investigator's choice. | Source → |
| New Combination Therapy Shows Promise in Treating Colorectal Cancer | Colorectal Cancer | phase-2 | Preliminary results demonstrate significant improvements in progression-free survival (PFS) and objective response rates. | Source → |
| Adding Panitumumab to Chemotherapy for Colon Cancer | Colorectal Cancer | phase-2 | There was a trend towards reduced recurrences with FOLFOX plus panitumumab compared with FOLFOX (12% versus 21%, hazard ratio = 0.51, P = 0.09) | Source → |
| Comparing Two Cancer Treatments in Metastatic Colorectal Cancer | Colorectal Cancer | phase-3 | There was no significant difference in median overall survival between treatment groups (9.1 months vs 10.1 months). | Source → |
| Combining Chemotherapy and Anti-EGFR Antibody May Help Some Colorectal Cancer Patients | Colorectal Cancer | meta-analysis | The pooled objective response rate was 85% (95% CI, 0.78-0.91; I = 58%) and the pooled rate of R0 resection was 42% (95% CI, 0.32-0.53; I = 62%). | Source → |
| Reusing Panitumumab in Advanced Colorectal Cancer | Colorectal Cancer | phase-2 | The 3-month progression-free survival rate was 50.0% (95% confidence interval 30.0-70.0). | Source → |
| Adding Panitumumab to Liver Cancer Treatment May Improve Survival | Colorectal Cancer | phase-2 | Twenty-five (69%; 95% CI, 53-82) patients in the Pmab arm were alive and recurrence-free at 15 months. | Source → |
| Panitumumab Exposure in Patients with Metastatic Colorectal Cancer | Colorectal Cancer | preclinical | — | Source → |
This information is provided for general education only and is not medical advice. Always consult a qualified healthcare professional before making treatment decisions.